 Cyclophosphamide
"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 3 | 4 | | 1996 | 1 | 3 | 4 | | 1997 | 1 | 3 | 4 | | 1998 | 0 | 3 | 3 | | 2000 | 1 | 3 | 4 | | 2001 | 0 | 4 | 4 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 3 | 5 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 3 | 3 | | 2008 | 1 | 6 | 7 | | 2009 | 3 | 4 | 7 | | 2010 | 0 | 3 | 3 | | 2011 | 2 | 6 | 8 | | 2012 | 2 | 4 | 6 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 10 | 11 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 7 | 8 | | 2018 | 1 | 3 | 4 | | 2019 | 0 | 6 | 6 | | 2020 | 3 | 6 | 9 | | 2021 | 1 | 7 | 8 | | 2022 | 0 | 7 | 7 | | 2023 | 0 | 8 | 8 | | 2024 | 4 | 4 | 8 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Kawano M, McKey J, Batchvarov IS, Capel B. Granulosa cell death is a significant contributor to DNA-damaging chemotherapy-induced ovarian insufficiency?. Biol Reprod. 2025 May 13; 112(5):906-915.
-
DuBois SG, Ogawa C, Moreno L, Moss? YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Georges GE, Khanna D, Wener MH, Mei MG, Mayes MD, Simms RW, Sanchorawala V, Hosing C, Kafaja S, Pawarode A, Holmberg LA, Kolfenbach J, Furst DE, Sullivan KM, Huang S, Gooley T, Nash RA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581.
-
Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereotactic Body Radiation Therapy Followed by FOLFIRINOX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2025 Mar 15; 121(4):930-941.
-
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Gui?ze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Dr?nou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, V?ron?se L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024 Aug 09; 15(1):6822.
-
Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921.
-
Wenderfer SE, Cooper JC. Do we really need cyclophosphamide for lupus nephritis? Pediatr Nephrol. 2024 Nov; 39(11):3193-3200.
-
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncol. 2024; 20(21):1455-1465.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|